Recent News

• 09.10.2025 - CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
• 09.10.2025 - CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
• 08.14.2025 - CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
• 08.14.2025 - CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
• 05.16.2025 - CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
• 05.16.2025 - CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
• 05.16.2025 - 28th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting

Recent Filings

• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 8-K Current report
• 06.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.27.2025 - 4 Statement of changes in beneficial ownership of securities